79 related articles for article (PubMed ID: 23000879)
1. Significantly decreased methylthioadenosine phosphorylase expression in malignant melanoma.
Gambichler T; Scola N; Bechara FG
Am J Dermatopathol; 2012 Oct; 34(7):777-9. PubMed ID: 23000879
[No Abstract] [Full Text] [Related]
2. Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions.
Minami S; Lum CA; Kitagawa KM; Namiki TS
Int J Dermatol; 2011 Jan; 50(1):24-9. PubMed ID: 21182498
[TBL] [Abstract][Full Text] [Related]
3. A potential predictive marker for response to interferon in malignant melanoma.
Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
[TBL] [Abstract][Full Text] [Related]
4. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
5. [Significance of human telomerase RNA expression in situ in malignant melanoma].
Wei Q; Fen S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):107-9. PubMed ID: 11938761
[TBL] [Abstract][Full Text] [Related]
6. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
7. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Bianchini F; Massi D; Marconi C; Franchi A; Baroni G; Santucci M; Mannini A; Mugnai G; Calorini L
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):320-8. PubMed ID: 17499752
[TBL] [Abstract][Full Text] [Related]
9. Expression of fatty acid synthase (FASN) in oral nevi and melanoma.
de Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; Graner E; de Almeida OP
Oral Dis; 2011 Nov; 17(8):808-12. PubMed ID: 21819495
[TBL] [Abstract][Full Text] [Related]
10. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions: morphological studies supporting cell adhesion function of DCXR.
Cho-Vega JH; Vega F; Schwartz MR; Prieto VG
J Cutan Pathol; 2007 Jul; 34(7):535-42. PubMed ID: 17576332
[TBL] [Abstract][Full Text] [Related]
11. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Behrmann I; Wallner S; Komyod W; Heinrich PC; Schuierer M; Buettner R; Bosserhoff AK
Am J Pathol; 2003 Aug; 163(2):683-90. PubMed ID: 12875987
[TBL] [Abstract][Full Text] [Related]
12. [Neuron-specific enolase (NSE)--a suitable tumor marker in malignant melanoma?].
Hornef S; Lux J; Rassner G
Hautarzt; 1992 Feb; 43(2):77-80. PubMed ID: 1347764
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma.
Chen Y; Chen Y; Huang L; Yu J
J Dermatol; 2012 Apr; 39(4):339-43. PubMed ID: 22150440
[TBL] [Abstract][Full Text] [Related]
14. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
15. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
16. The role of nm23 in melanoma progression and its prognostic significance.
Betke H; Korabiowska M; Brinck U; Trybus-Gałuszka H; Kellner S; Okoń K; Stachura J; Droese M
Pol J Pathol; 1998; 49(2):93-6. PubMed ID: 9798412
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
18. [Tyrosinases of nevo-cellular nevi and human malignant malanomas].
Voulot C; Ortonne JP
Ann Dermatol Syphiligr (Paris); 1975; 102(5-6):547-51. PubMed ID: 821383
[No Abstract] [Full Text] [Related]
19. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
[TBL] [Abstract][Full Text] [Related]
20. Placental alkaline phosphatase positivity in metastatic melanoma.
Frieling GW; Al-Zaid T; Prieto VG
Am J Dermatopathol; 2014 Feb; 36(2):189-90. PubMed ID: 24561965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
